Richard A. Mortimer

Education

Ph.D., economics, University of California, Berkeley; B.A., economics, the Johns Hopkins University

Summary of Experience

Dr. Mortimer specializes in health economics, industrial organization, microeconomic theory, and econometrics. He has extensive experience with issues involving competition, intellectual property, marketing, pricing, and valuation with a focus on the health care industry. He has evaluated questions of class certification, damages, liability, and market definition in antitrust matters. He also has provided economic analyses and expert testimony on causation, damages, and valuation in a variety of health care cases, including cases involving allegations of False Claims Act (FCA), Anti-Kickback Statute (AKS), and Lanham Act violations. In addition to his work in litigation, Dr. Mortimer has assisted pharmaceutical and medical device manufacturers on pricing and contracting issues and authored several public policy studies related to legislation establishing a biosimilar approval pathway, biosimilar competition, pharmaceutical pricing, generic drug competition and the role of authorized generic entry, and paragraph IV abbreviated new drug application (ANDA) filings. His research has been published in leading peer-reviewed journals, including Health Affairs, Nature Reviews Drug Discovery, The Journal of Industrial Economics, and the Journal of Medical Economics.

• Authorized Generics, Competition, and Consumer Prices
• In re: HIV Antitrust Litigation
• Pharmaceutical Off-Label Promotion & Kickbacks Settlements

• Continuing trends in U.S. brand-name and generic drug competition

  Journal of Medical Economics, 2021
  2021

  Grabowski H, Long G, Mortimer R, Bilginsoy M

  HEOR, Epidemiology & Market Access
• Cardiac arrhythmia detection outcomes among patients monitored with the Zio patch system: a systematic literature review

  Current Medical Research and Opinion, 2019
  2019

  Yenikomshian M, Jarvis J, Patton C, Yee C, Mortimer R, Birnbaum H, Topash M

  HEOR, Epidemiology & Market Access
• The Economics of Biosimilar Drugs and New Considerations in Intellectual Property and Antitrust Litigation

  Public Domain: The Newsletter of the ABA Section of Antitrust Law’s Intellectual Property Committee, July 2018
  2018

  Mortimer R, Ellman B

  Antitrust & Competition, HEOR, Epidemiology & Market Access, Intellectual Property
• The Rise of Biosimilars and the Future of Healthcare Intellectual Property

  IAM, November/December 2018
  2018

  Mortimer R, Ellman B

  HEOR, Epidemiology & Market Access, Intellectual Property
• Can The Life Sciences Industry Bank On Biosimilars?

  Law360, April 13, 2016
  2016

  Greenberg P, Sisitsky T, Mortimer R

  HEOR, Epidemiology & Market Access
• Correlation Or Cause: Brand-Name Drug Prescription Rates

  Law360, March 23, 2016
  2016

  Greenberg P, Sisitsky T, Mortimer R

  HEOR, Epidemiology & Market Access
• The Potential For Litigation In New Era Of Biosimilars

  Law360, September 20, 2016
  2016

  Frois C, Mortimer R, White A

  Antitrust & Competition, HEOR, Epidemiology & Market Access, Intellectual Property
• Updated trends in US brand-name and generic drug competition

  Journal of Medical Economics, 2016 04: 1-9. e-pub ahead of print 2016/04/12
  2016

  Grabowski H, Long G, Mortimer R, Boyo A

  HEOR, Epidemiology & Market Access
• Recent Trends in Brand Name and Generic Drug Competition

  Journal of Medical Economics, March 2014
  2014

  Grabowski H, Long G, Mortimer R

  HEOR, Epidemiology & Market Access, Strategy, Policy & Analytics
• Recent Average Price Trends for Implantable Medical Devices, 2007-2011

  White Paper
  2013

  Long G, Mortimer R, Sanzenbacher G

  HEOR, Epidemiology & Market Access, Strategy, Policy & Analytics
• Data Exclusivity for Biologics

  Nature Reviews Drug Discovery 10, 15-16 (January 2011) - doi:10.1038/nrd3277
  2011

  Long G, Mortimer R, Grabowski H

  HEOR, Epidemiology & Market Access, Intellectual Property, Strategy, Policy & Analytics
• Evolving Brand-Name and Generic Drug Competition May Warrant a Revision of the Hatch-Waxman Act

  Health Affairs, 2011, 30(11), 2157-2166
  2011

  Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N

  HEOR, Epidemiology & Market Access, Intellectual Property, Strategy, Policy & Analytics
• Implementation of the Biosimilar Pathway: Economic and Policy Issues

  Seton Hall Law Review, Book 2, 41:2
  2011

  Grabowski HG, Long G, Mortimer R

  HEOR, Epidemiology & Market Access, Intellectual Property, Strategy, Policy & Analytics
• Data Exclusivity Periods and Next Generation Improvements to Innovator Biologics: Key Issues

  Duke University Department of Economics Working Paper, No. 2009-05
  2009

  Grabowski H, Cockburn I,  Long G,  Mortimer R

  HEOR, Epidemiology & Market Access
• Data Exclusivity Periods for Biologics: Updating Prior Analyses and Responding to Critiques

  Duke University Department of Economics Working Paper, No. 2008-10
  2008

  Grabowski H, Long G, Mortimer R

  HEOR, Epidemiology & Market Access
• The Effect on Federal Spending of Legislation Creating a Regulatory Framework for Follow-on Biologics: Key Issues and Assumptions

  White Paper
  2007

  Grabowski H, Cockburn I, Long G, Mortimer R, Johnson S

  HEOR, Epidemiology & Market Access
• Authorized Generic Drugs, Price Competition, And Consumers’ Welfare

  Health Affairs - 26, no. 3 (2007): 790-799
  2007

  Berndt E, Parece A, Tuttle E, Mortimer R, Bhattacharjya A

  HEOR, Epidemiology & Market Access, Strategy, Policy & Analytics
• Do Authorized Generic Drugs Deter Paragraph IV Certifications? Recent Evidence

  Working Paper: April 17, 2007
  2007

  Berndt E, Mortimer R, Parece A

  HEOR, Epidemiology & Market Access, Strategy, Policy & Analytics

• February 6, 2024

  GCR Antitrust Awards 2024: Analysis Group Case Work and Academic Affiliate Anupam Jena Nominated for Multiple Competition Awards

  Antitrust & Competition, Commercial Disputes, Health Care, Technology
• August 8, 2023

  Dr. Anupam B. Jena, an Analysis Group Affiliate, Provides Testimony in Gilead Science’s Successful Defense of Pay-for-Delay Allegations of HIV Treatments

  Antitrust & Competition, Health Care